Is β-Arrestin 2 a Magic Bullet for Heart Failure Treatment?

This publication has 14 references indexed in Scilit:

• Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial
  The Lancet, 2016
• Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2
  Circulation Research, 2015
• Negative Impact of β-Arrestin-1 on Post-Myocardial Infarction Heart Failure via Cardiac and Adrenal-Dependent Neurohormonal Mechanisms
  Hypertension, 2014
• Heart Failure
  JACC: Heart Failure, 2013
• Compartmentalization of β-Adrenergic Signals in Cardiomyocytes
  Circulation Research, 2011
• Physiologic and cardiac roles of β-arrestins
  Journal of Molecular and Cellular Cardiology, 2009
• Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals
  Gene Therapy, 2008
• Differential Extracellular Signal‐Regulated Kinases 1 and 2 Activation by the Angiotensin Type 1 Receptor Supports Distinct Phenotypes of Cardiac Myocytes
  Basic & Clinical Pharmacology & Toxicology, 2007
• Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart.
  Circulation Research, 1994
• Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts
  New England Journal of Medicine, 1982